Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025

Rapport Therapeutics, Inc.

Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.
Phase 2a trial of RAP-219 in refractory focal epilepsy topline results expected Q3 2025 (narrowed timeline).
Appointed Jeffrey Sevigny, M.D., as chief medical officer, effective immediately.
Cash and investments $305.3M at year-end; expected to fund operations through end of 2026.
FDA placed IND for Phase 2a DPNP trial on clinical hold; company finalizing trial plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.